Stone Age boomerang is oldest in Europe — and possibly the world
When you buy through links on our articles, Future and its syndication partners may earn a commission.
An unusual mammoth tusk boomerang discovered in a cave in Poland is 40,000 years old — making it Europe's first example of this complex tool and possibly the oldest boomerang in the world, a new study finds.
"The ivory object has all the features of boomerangs used by Aborigines in Queensland today," study co-author Paweł Valde-Nowak, an archaeologist at Jagiellonian University in Krakow, Poland, told Live Science in an email. "Its arched shape, flat-convex cross-section and dimensions match the Queensland boomerangs that do not return to the thrower," he said.
The new study, published Wednesday (June 25) in the journal PLOS One, shows that curved throwing tools were invented in Europe far earlier than expected.
The crescent-shaped artifact — which is about 28 inches (72 centimeters) long — was found in Obłazowa Cave in southern Poland 40 years ago along with human bones, pendants made from fox fangs, and stone blade tools, all covered with red ocher. Valde-Nowak and colleagues published their original findings in the journal Nature in 1987, suggesting the cave was used off and on by Neanderthals and early humans during the Middle to Upper Paleolithic periods (300,000 to 12,000 years ago).
The Upper Paleolithic (50,000 to 12,000 years ago) is a key period in human history, as humans invented new forms of tools, cave art and personal decoration. And at Obłazowa Cave, Valde-Nowak saw a clear difference between the ocher-covered finds and earlier artifacts at the same site.
"In my opinion, this is absolutely clear evidence of behaviors unknown to us, practices of early Homo sapiens, which contrast sharply with everything we found in the deeper cultural layers in Obłazowa, layers left by Neanderthals," Valde-Nowak said.
Related: This man was killed by brutal boomerang blow 800 years ago
To better understand the chronology of the Obłazowa Cave, in 1996 the researchers performed a carbon-14 analysis on organic remains discovered in the cave, including the ivory boomerang. However, at 18,000 years old, the boomerang was "unexpectedly young," raising concerns that the results had been skewed by contamination from adhesives or conservation material, the researchers wrote in the new study.
Evidence of classic Aboriginal boomerangs and throwing sticks dates back at least 20,000 years, according to the National Museum of Australia. These boomerangs are multi-use tools, often used for hunting, fighting or digging. But people around the world have fashioned throwing sticks, including one very early example from northern Germany dating back 300,000 years.
In the new analysis of finds from Obłazowa Cave, the researchers undertook DNA and radiocarbon analyses of a human finger bone from the boomerang layer and determined that the person was a modern human who lived at least 31,000 years ago. The researchers also analyzed a dozen animal bones, but not the boomerang itself, "to avoid further damage to this highly significant artifact," they wrote in the study.
RELATED STORIES
—5 non-returning Aboriginal boomerangs discovered in dried-up riverbed
—Ancient Indigenous weapons from Australia can deliver 'devastating blows,' 1st-ever biomechanics study of its kind reveals
—12,000-year-old Aboriginal sticks may be evidence of the oldest known culturally transmitted ritual in the world
A cluster of animal bones found in the same layer as the boomerang all dated to around 41,500 years ago. Given this series of radiocarbon dates and the depths of the bones within the layer, the researchers created a statistical model for the date of the boomerang, finding that it was definitely made more than 35,000 years ago and that it was most likely carved between 42,365 and 39,355 years ago.
"Our analysis on the boomerang found at the Obłazowa site has yielded groundbreaking insights into its age," the researchers wrote, positioning the boomerang "as potentially one of the oldest specimens in Europe, and possibly globally, thereby shedding light on both technical skills and cognitive advancements of Homo sapiens in crafting these complex tools."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
34 minutes ago
- Medscape
Novel Drug Lowers Urate Levels but Gout Flares Persist
BARCELONA, Spain — The investigational oral compound SAP-001 had a significant and sustained urate-lowering effect in people with refractory gout, according to findings of a phase 2b study reported at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. The proportion of people achieving a target serum urate level of < 6 mg/dL (360 µ mol/L) after 12 weeks was 10.5% for placebo and ranged from 43.8% to 70.0% for those given one of three different once-daily doses of SAP-001. A dose response was not seen in the main analysis, however; the proportions of people meeting this primary efficacy endpoint were 43.8% (n = 32) for a 60-mg dose but 56.3% (n = 16) and 70.0% (n = 20) for 10- and 30-mg doses, respectively. Kenneth Saag, MD This could have been because of issues with adherence, said the presenting author Kenneth Saag, MD, professor and director of the Division of Clinical Immunology and Rheumatology at The University of Alabama at Birmingham. Ad hoc analyses, which had not been preplanned, showed that 'some subjects had not been exposed to the drug post baseline,' Saag said. 'This seemed to strongly correlate with adherence to therapy, as indicated by [a patient's daily] dosing diary, pill counts, and post-study patient interviews.' When people with nonquantifiable serum urate levels were excluded from the analyses, there was more of a dose response, particularly if a lower urate level of < 5 mg/dL (300 µ mol/L) had been achieved. Notably, Saag reported that the urate-lowering effects were maintained until the end of treatment at 6 months, and a good proportion of participants also met the harder target of a serum urate level of < 5 mg/dL. First-in-Class 'SAP-001 is a drug that has a different renal urate transporter mechanism of action from other urate-lowering drugs that are currently available or are under development,' said Saag, a former president of the American College of Rheumatology. Although Saag did not present the specific mode of action for the drug, he noted, 'it appears to predominantly be targeting GLUT [glucose transporter] 9, which is located on the basal lateral aspect of the renal tubule.' This differs from most other uricosuric therapies, which targeted renal transporters on 'the apical side of the tubule, such as OAT [organic anion transporters] and URAT [urate transporter]-1,' he added. 'So this drug has the potential as a novel therapeutic option in gout,' Saag said. Study Design and Patient Population The study was a 6-month randomized, double-blinded, placebo-controlled investigation of three different doses of SAP-001 for the management of refractory gout. A total of 403 adults with refractory gout between 18 years and 75 years of age who were living in the US were screened for eligibility, with 87 finally randomized. For inclusion, participants had to either have not responded to at least 4 weeks of standard of care treatment with a xanthine oxidase inhibitor prior to study entry or have a contraindication to its use. They also had to have serum urate levels of ≥ 7 mg/dL at both the screening and randomization visit. A 1:1:1:2 ratio was used to randomly allocate participants to the four treatment groups: placebo or SAP-001 10 mg, 30 mg, or 60 mg. Baseline characteristics were reasonably similar among the four groups. The mean ages in each group were 55.9 years, 54.2 years, 50.3 years, and 52.5 years, respectively. The majority were men (89.5%, 87.5%, 90.0%, and 96.9%, respectively), and most identified themselves as White and Hispanic individuals. The mean BMI was around 32, and baseline serum urate levels were about 8.37 mg/dL (~500 µ mol/L). The average duration of gout since diagnosis was about 10 years, and 1 in 5 had palpable tophi. Safety Findings Saag and associates reported in their abstract that SAP-001 was well tolerated overall. There were no treatment-emergent serious adverse events in the SAP-001 patients, and all adverse events were of a mild to moderate intensity. The most frequently reported adverse events were gout flares; these occurred in 26.3% of placebo-treated individuals and in 25%, 30%, and 25% of participants treated with SAP-001 10 mg, 30 mg, and 60 mg, respectively. The majority of these gout flares occurred within the first few months of the study, although some people taking SAP-001 experienced gout flares up to 4-6 months later. The longest duration of gout flares in the SAP-001 groups was 11.5 days in the 60-mg SAP-001 group, and the shortest was 6.2 days in the 30-mg group. The mean durations of gout flares in the 10-mg and placebo groups were 6.5 and 7.4 days, respectively. The time to the first gout flare was shortest in the 30-mg SAP-001 group, at 21.2 days, followed by 40.5 days in the 60-mg group, 50.3 days in the 10-mg group, and 66.4 days in the placebo group. As for adverse events of special interest, one participant who had taken the 30-mg dose of SAP-001 developed a hepatobiliary disorder, and another who had taken this dose had raised aspartate aminotransferase, an outcome that also occurred in one patient each in the 10- and 60-mg dosing groups. Increased blood creatinine levels were seen in two participants in the 10-mg group and three in the 60-mg group. Hepatic enzymes were elevated in one patient in the placebo group and one patient in the 30-mg group. One patient in the 60-mg group had acute kidney injury. Limitations and Conclusion Saag acknowledged that this was an early-phase study, and its small sample size meant the effect on flares and tophi was limited. However, he concluded that SAP-001 may be a 'novel, efficacious, and generally safe oral urate-lowering treatment option for difficult-to-treat gout populations, and it merits further investigation with a focus on treatment adherence.' Helga Lechner-Radner, Wien, Austria, who co-chaired the late-breaking abstract session during which Saag had presented these data, questioned whether people with genetic conditions that could cause hyperuricemia had been included or excluded from the study. Saag responded: 'That wasn't specifically a form of [inclusion]/exclusion in this study; in future studies, that would certainly be reasonable to look at.' This study was funded by Shanton Pharma. Saag reported acting as a consultant to Shanton Pharma as well as Amgen, Arthrosi, ATOM, Crystalys, LG, and Sobi. He also reported being an investigator for Arthrosi, Crystalys, Inventis, and LG. Several coauthors on the abstract were employees of Shanton Pharma.


Bloomberg
an hour ago
- Bloomberg
What Makes Axiom 4 Truly Historic?
Astronauts from the US, India, Poland and Hungary are on their way to the ISS after SpaceX's successful launch of the Axiom 4 mission. Here's what sets it apart. (Source: Bloomberg)
Yahoo
2 hours ago
- Yahoo
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
Upstream phase of LUMEVOQ® manufacturing process successfully transferred Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and dose-ranging study in France Partnership expected to improve yield and upgrade analytical methods ahead of clinical use and regulatory submissions PARIS, June 26, 2025--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ®, the Company's gene therapy candidate product for the rare mitochondrial disease Leber Hereditary Optic Neuropathy (LHON), to its new manufacturing partner, Catalent, Inc. "This outstanding result is a significant milestone in GenSight's strategy for securing the supply of LUMEVOQ for clinical use and for supporting the planned regulatory submissions," commented Scott Jeffers, Chief Technical Officer of GenSight Biologics. "Our new partnership is proving to be highly effective, not just in completing the tech transfer process successfully, but also in improving the yield and upgrading the analytical methods used to reinforce control over the safety and quality of each batch. The level of collaboration and coordination between our teams has been truly impressive." Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. It is the only CDMO with a successfully commercialized gene therapy produced in their facility. Catalent offers gene therapy companies both production and in-house testing capabilities, and the GMP capacity at the facility used for LUMEVOQ® will provide GenSight Biologics greater flexibility in the manufacture of the gene therapy. Catalent successfully manufactured the drug product batch that was released as safe for human use in November 2024 and which will be the source of product supply for the named patient early access program (AAC) and dose-ranging study in France. After the tech transfer is completed, Catalent will also manufacture the drug for the planned global Phase III trial RECOVER and the regulatory submissions. The Partnership as a Critical Element of GenSight Biologics' Strategy Following agreement with the French agency ANSM to consider opening the AAC program expeditiously after approval of a dose-ranging study, the Company is currently implementing a financing strategy, as it continues to advance its global marketing authorization strategy: Preparation for regulatory consultations in the US and EU Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements Completing the transition to a new manufacturing partner (Catalent) to secure reliable clinical and commercial supply Advancing preparations for MHRA submission in the United Kingdom "Our partnership with a manufacturing powerhouse like Catalent is a critical enabler of our global strategy," explained Laurence Rodriguez, CEO of GenSight Biologics. "The outputs from their work with our team will allow us to reassure regulators that we have surmounted the challenges we faced in the past and, ultimately, to fulfill our mission to provide LHON patients a safe and effective treatment for their urgent unmet need." About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. About Leber Hereditary Optic Neuropathy (LHON) Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1st eye, with the 2nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of subjects have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously. About LUMEVOQ® (GS010; lenadogene nolparvovec) LUMEVOQ® (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. "LUMEVOQ" was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018. LUMEVOQ® (GS010; lenadogene nolparvovec) has not been registered in any country at this stage. View source version on Contacts GenSight Biologics Chief Financial OfficerJan Eryk Umiastowskijeumiastowski@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data